Flexible-dose long-term H (not >20,000 U/day) reduced first-year and total mortality in patients with severe or high-risk coronary disease. What kept patients on these regimens, however, was symptomatic improvement and lessened incidence of new CV events. Experience since 1975 with the survivors of this series and with 40 additional CAD patients remains consistent, and supports the hypothesis that our long-term H regimens can favorably and safely alter the natural history of coronary heart disease and its vascular complications. The mechanisms, probably multiple, involve sustained increases in the patients' heparin pools. Study of these and wider usage are needed.
|Original language||English (US)|
|Number of pages||4|
|Journal||Annals of the New York Academy of Sciences|
|State||Published - 1989|
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)